[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Doval DC, Pande SB, Sharma JB, Rao SA, Prakash N, Vaid AK: Report of a case of pericardial mesothelioma with liver metastases responding well to pemetrexed and platinum-based chemotherapy. J Thorac Oncol; 2007 Aug;2(8):780-1
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Report of a case of pericardial mesothelioma with liver metastases responding well to pemetrexed and platinum-based chemotherapy.
  • Pericardial mesothelioma remains a disease with a bleak prognosis.
  • We report the case of a patient with metastases to liver and good response to pemetrexed and carboplatin-based combination chemotherapy and consequent prolonged progression-free survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Heart Neoplasms / pathology. Liver Neoplasms / secondary. Mesothelioma / secondary. Pericardium

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762349.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glutamates; 0 / Platinum Compounds; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


2. Génébès C, Brouchet L, Kamar N, Lepage B, Prévot G, Rostaing L, Didier A, Mazières J: Characteristics of thoracic malignancies that occur after solid-organ transplantation. J Thorac Oncol; 2010 Nov;5(11):1789-95
MedlinePlus Health Information. consumer health - Organ Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Among a cohort of 2831 patients who received a transplant at our institution and were followed between 1984 and 2009, 24 patients (0.85%) developed thoracic malignancies.
  • The most frequent histologic types were squamous cell carcinoma (n = 11, 46%) and adenocarcinoma (n = 9, 37%).
  • The median time period between transplantation and diagnosis of lung cancer was 6.6 years.
  • Ten lung malignancies occurred after kidney transplantation (0.5%), eight after liver transplantation (1.3%), and six after heart transplantation (2.8%).
  • Seven patients underwent surgery, three had radiotherapy, four had chemotherapy, and six had multimodal treatment.
  • The median survival time was 1.5 years, ranging from 6 months for stage IV to 3.7 years for stage I.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Squamous Cell / etiology. Lung Neoplasms / etiology. Mesothelioma / etiology. Organ Transplantation / adverse effects. Small Cell Lung Carcinoma / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20975378.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW: Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res; 2001 Feb;7(2):231-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The in vitro chemosensitivity of cancer cells to ET-743 is markedly enhanced by prolonging the duration of exposure to the drug.
  • (d) Eastern Cooperative Oncology Group performance status < or = 1, 20 patients; and (e) two prior regimens of chemotherapy, 7 patients.
  • Reversible grade 4 transaminitis occurred in two of nine patients after treatment with the first cycle of therapy at the third dose level of 1200 microg/m2.
  • Another patient experienced grade 4 rhabdomyolysis, renal failure requiring hemodialysis, grade 4 neutropenia, and grade 3 thrombocytopenia during the second cycle of therapy with this dose.
  • Toxicity of the drug is clearly schedule-dependent, because increasing the duration of infusion from 3 or 24 h to 72 h results in decreased myelosuppression and comparable hepatotoxicity.
  • Although there were no objective responses to therapy, clear evidence of antitumor activity was observed in a patient with epithelioid mesothelioma, as confirmed by positron emission tomography studies.
  • The therapeutically optimal administration schedule remains to be established, inasmuch as there have been indications of activity against a variety of tumors during Phase I studies when the drug was infused over times ranging from 1 to 72 h.
  • Characterizing the pharmacokinetics of ET-743 during the course of Phase II trials and Phase I combination studies is recommended to assure that this promising new anticancer drug can be used with an acceptable margin of safety.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alanine Transaminase / metabolism. Area Under Curve. Aspartate Aminotransferases / metabolism. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Liver / drug effects. Male. Maximum Tolerated Dose. Middle Aged. Models, Chemical. Tetrahydroisoquinolines. Time Factors. Toxicity Tests

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11234874.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


Advertisement
4. Noguchi T, Kawamura M, Kawamura T, Shimamura T, Sasaki K, Hosono T, Sato R, Murakami K: [A case of diffuse peritoneal malignant mesothelioma--intraabdominal administration of cisplatin is useful for diminishing ascites]. Gan To Kagaku Ryoho; 2010 Oct;37(10):1975-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of diffuse peritoneal malignant mesothelioma--intraabdominal administration of cisplatin is useful for diminishing ascites].
  • We suspected diffuse malignant peritoneal mesothelioma because hyaluronate in ascites rose to 10×10⁴ ng/mL.
  • The result of biopsy was malignant mesothelioma.
  • He lived for a year with no recurrence but died 23 months after diagnosis because of progression of pleural mesothelioma and liver metastases.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Mesothelioma / drug therapy. Peritoneal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948267.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Torrejón Reyes PN, Frisancho O, Gómez A, Yábar A: [Malignant peritoneal mesothelioma]. Rev Gastroenterol Peru; 2010 Jan-Mar;30(1):82-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peritoneal mesothelioma].
  • The peritoneal mesothelioma is a rare pathology with unspecific symptoms reason to be a difficult diagnosis.
  • We report a case of a 58 year old man with diabetes mellitus type 2, arterial hypertension and smoking; without precedent of asbestos exposure.
  • The abdomen distended by ascites, not painful, liver and spleen not examined.
  • Cytology: mesothelial cells with changes of type reagent, Block cell for tumour cells: negative.
  • The report of the peritoneal biopsy was informed as suggestive of undifferentiated carcinoma; the reappraisal with inmunohystochemic (calretinin +,cytokeratin +, vimentin +) indicated malignant peritoneal mesothelioma, type epithelial.
  • The patient was transferred to the Service of Oncology where they initiated chemotherapy with Cysplatin (CDDP) and died 20 days later.
  • The malignant mesothelioma peritoneal is a unfrequent entity, with limited therapeutic options; generally detected late, with a palliative treatment.
  • [MeSH-major] Mesothelioma. Peritoneal Neoplasms

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20445731.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down


6. Uría González-Tova J, Escalera Almendros C, Sánchez Macias J, Areal Calama J, Sanfeliú Cortes F, Ibarz Servio L, Saladie Roig JM: [Malignant mesothelioma of the tunica vaginalis]. Actas Urol Esp; 2000 Oct;24(9):757-60
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant mesothelioma of the tunica vaginalis].
  • Case report of a new case of malignant mesothelioma of the tunica vaginalis testis.
  • After surgery (orchiectomy and partial hemiscrotectomy) and histopathology diagnosis of locally advanced malignant mesothelioma, CT showed metastasis in retroperitoneum, Lung and Liver.
  • The patient undergoes chemotherapy and radiotheraphy with a poor prognose.
  • [MeSH-major] Mesothelioma / pathology. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11132449.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


7. Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M: Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol; 2009 Feb;16(2):463-72
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
  • Improved survival has been reported for diffuse malignant peritoneal mesothelioma (DMPM) treated by cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
  • The issue of treatment failure has never been extensively addressed.
  • The present study assessed the failure pattern, management, and outcome of progressive DMPM following comprehensive treatment.
  • Median time to progression was 9 months [95% confidence interval (CI) 1.6-35.9].
  • The failure pattern was categorized as peritoneal progression (n = 31), liver metastases (n = 1), abdominal lymph-node involvement (n = 2), pleural seeding (n = 4).
  • Progressive disease was treated with second HIPEC in 3 patients, debulking in 4, systemic chemotherapy in 16, and supportive care in 15.
  • At multivariate analysis, time to progression <9 months (P = 0.009), poor performance status (P = 0.005), and supportive care (P = 0.003) correlated to reduced survival from progression.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Mesothelioma / therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm, Residual / diagnosis. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Disease Progression. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Prognosis. Prospective Studies. Survival Rate. Treatment Failure. Young Adult

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19082859.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Takeuchi N, Nakai M, Sato M: [A case of omental mesothelioma presenting with laminar thickening of omentum-appearances of diffuse malignant peritoneal mesothelioma]. Gan To Kagaku Ryoho; 2008 Apr;35(4):677-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of omental mesothelioma presenting with laminar thickening of omentum-appearances of diffuse malignant peritoneal mesothelioma].
  • A man in his 60's with no apparent history of asbestos exposure was admitted to our hospital with a chief complaint of abdominal fullness.
  • Furthermore, the thickened omentum was clearly visualized by lowering the signal for the liver and spleen by SPIO and by suppressing the ascites signal by fluid-attenuated inversion recovery (FLAIR).
  • Chemotherapy was ineffective, and the patient died of liver metastasis in February 2006.
  • Autopsy confirmed biphasic malignant peritoneal mesothelioma.
  • The involvement of asbestos is clear in the onset of malignant peritoneal mesothelioma.
  • Hence, when levels of CA125 in serum and/or ascites are high, it is important to differentiate malignant peritoneal mesothelioma from primaryserous papillary carcinoma of the peritoneum.
  • Here, we experienced a case of biphasic diffused omental mesothelioma.
  • Laminar thickening of the omentum and short mesentery are thought to be characteristic features of diffused peritoneal mesothelioma when subjective symptoms appear.
  • In the future, we hope to differentiate epithelial, sarcomatous and biphasic types based on imaging findings.
  • [MeSH-major] Mesothelioma / pathology. Mesothelioma / radiography. Omentum / pathology. Omentum / radiography
  • [MeSH-minor] Aged. Diffusion. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radionuclide Imaging. Tomography, X-Ray Computed. Treatment Failure

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18408444.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Serke M, Loddenkemper R: [Therapeutic options in malignant pleural mesothelioma]. Pneumologie; 2005 May;59(5):337-48
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic options in malignant pleural mesothelioma].
  • Malignant pleural mesothelioma may be treated with surgery, radiotherapy and chemotherapy.
  • In most patients, the treatment remains palliative with symptom relief and a moderate survival gain.
  • Only a minority of patients with early stage mesothelioma may be cured by a multimodal approach including radical surgery, chemotherapy, and radiotherapy.
  • We discuss the role of surgery with either radical extrapleural pleuropneumonectomy or less invasive palliative pleurectomy and decortication, and the role of radiotherapy, in which the main problem is how to deliver sufficient doses to the pleural surface, sparing radiosensitive structures such as the lung, heart, liver, and kidneys.
  • Chemotherapeutic options are discussed with 'older' mono- and combination regimens and the new promising combination cisplatinum/pemetrexed, now the 'standard regimen' for malignant pleural mesothelioma.
  • For the majority of our patients we recommend talcum pleurodesis either by medical thoracoscopy or VATS, followed by chemotherapy with platinum/pemetrexed.
  • The individual therapeutic decision will depend on tumour stage, concomitant diseases, performance status, and on the patient's preference.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902599.001).
  • [ISSN] 0934-8387
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 103
  •  go-up   go-down


10. Akagi S, Ozaki S, Kishimoto T: [A case of splenic hemorrhage in the course of malignant mesothelioma]. Nihon Kokyuki Gakkai Zasshi; 2004 Mar;42(3):253-6
MedlinePlus Health Information. consumer health - Spleen Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of splenic hemorrhage in the course of malignant mesothelioma].
  • Chest computed tomography showed tumors which projected from the pleura of the right upper and lower lung fields.
  • Malignant mesothelioma was diagnosed by biopsy of the pleura via echogram.
  • Both chemotherapy and radiotherapy were administered because of brain metastasis and direct rib invasion.
  • Under this combined therapy, sudden anemia and hypotension appeared due to splenic hemorrhage, which suggested splenic metastasis of the malignant mesothelioma.
  • Multiple metastases in, for example, the spleen, brain, lung, liver, duodenum, small intestine, kidney, adrenal gland, vertebra, thyroid gland, and lymph nodes were confirmed by autopsy.
  • Distant metastasis is rare for malignant mesothelioma, and we report here a case of splenic metastasis with splenic hemorrhage in malignant mesothelioma.
  • [MeSH-major] Hemorrhage / etiology. Mesothelioma / secondary. Pleural Neoplasms / pathology. Splenic Diseases / etiology. Splenic Neoplasms / secondary

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15069782.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial. Prescrire Int; 2005 Dec;14(80):212-4
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
  • (1) Chemotherapy does not appear to prolong the survival of patients with inoperable pleural mesothelioma, and the tumour response rate barely exceeds 20%.
  • A combination of cisplatin + doxorubicin seems to provide the best response rates. (2) In a trial of second-line docetaxel therapy in patients with non small cell lung cancer, survival was extended by about 3 months compared with palliative care (7.5 versus 4.6 months). (3) Pemetrexed, an antifolate closely related to methotrexate and raltitrexed, has been authorized for use for both conditions. (4) In a randomised single-blind trial involving 456 patients with previously untreated pleural mesothelioma, survival was prolonged by about 3 months by a cisplatin + pemetrexed combination in comparison with cisplatin + placebo (12.1 versus 9.3 months).
  • This is the only available comparative trial of pemetrexed in patients with mesothelioma.
  • A more appropriate comparator would have been a cisplatin-based regimen such as cisplatin + doxorubicin. (5) A "non inferiority" trial of second-line treatment in 571 patients with locally advanced or metastatic non small cell lung cancer showed no significant difference in median survival time with pemetrexed versus docetaxel (about 8 months with both treatments).
  • However, this trial does not rule out the possibility that pemetrexed is less effective than docetaxel. (6) Supplementation with folic acid and vitamin B12 reduces haematological and gastrointestinal complications associated with the antifolate activity of pemetrexed. (7) Despite this supplementation, more than 15% of patients in the mesothelioma trial developed severe neutropenia, leukopenia or fatigue during cisplatin + pemetrexed therapy.
  • Pemetrexed aggravates the nausea and vomiting provoked by cisplatin, a drug that is highly emetic. (8) The adverse effects of pemetrexed were similar to those of docetaxel in the trial comparing the two drugs.
  • However, neutropenia (5% versus 40%) and febrile neutropenia (2% versus 13%) occurred less frequently with pemetrexed. (9) Patients receiving pemetrexed must be monitored closely for some rare but potentially severe adverse effects; they include angina, myocardial infarction and stroke, liver damage, and bullous skin rash. (10) According to the summary of product characteristics (SPC), pemetrexed therapy must be administered in combination with folic acid and vitamin B12 supplementation in order to reduce haematological toxicity, and also with corticosteroid therapy to reduce the risk of serious skin reactions. (11) In practice, given the absence of a better alternative, and pending the results of a second trial, the cisplatin + pemetrexed combination can be used as a first-line regimen for patients with pleural mesothelioma.
  • However, pemetrexed cannot replace docetaxel in second-line treatment of non small cell lung cancer.
  • [MeSH-major] Glutamates / therapeutic use. Guanine / analogs & derivatives. Guanine / therapeutic use. Lung Neoplasms / drug therapy. Mesothelioma / drug therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / therapeutic use. Clinical Trials as Topic. Drug Therapy, Combination. Drugs, Investigational. Humans. Neoplasm Metastasis. Taxoids / administration & dosage. Taxoids / adverse effects. Taxoids / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400741.001).
  • [ISSN] 1167-7422
  • [Journal-full-title] Prescrire international
  • [ISO-abbreviation] Prescrire Int
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Investigational; 0 / Glutamates; 0 / Taxoids; 5Z93L87A1R / Guanine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Kuku I, Kaya E, Sevinc A, Aydogdu I: Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothelioma. J Eur Acad Dermatol Venereol; 2002 May;16(3):271-2
Genetic Alliance. consumer health - Mesothelioma, malignant.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothelioma.
  • Gemcitabine is a nucleoside analogue that has shown to have antineoplastic activity in different solid tumours (lung, pancreas, bladder, colon, ovarian, and breast cancer) and malignant mesothelioma.
  • The toxic effects of gemcitabine include myelosuppression, flu-like syndrome, altered liver function tests, bronchospasm, rash, itching, and fever.
  • We reported a male patient who developed erysipeloid skin reaction following gemcitabine treatment in the absence of radiotherapy and lymphedema.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Drug Eruptions / etiology. Erysipeloid / chemically induced
  • [MeSH-minor] Humans. Liver Neoplasms / drug therapy. Male. Mesothelioma / drug therapy. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12195570.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


13. Saleem A, Ranson M, Callies S, Lahn M, Prenant C, Brown G, Matthews JC, Dence CS, McMahon A, Price P: Microdosing imaging pharmacokinetic (PK) study of the antisense oligonucleotide (ASO) to survivin (LY2181308) using positron emission tomography (PET): A novel paradigm in clinical drug development. J Clin Oncol; 2009 May 20;27(15_suppl):3578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microdosing imaging pharmacokinetic (PK) study of the antisense oligonucleotide (ASO) to survivin (LY2181308) using positron emission tomography (PET): A novel paradigm in clinical drug development.
  • [<sup>11</sup>C]LY2181308-PET scans were performed at baseline and during treatment infusion.
  • [<sup>11</sup>C]LY2181308 uptake in normal tissue and tumour was quantified.
  • Despite its large size (6778 amu), [<sup>11</sup>C]LY2181308 rapidly distributed to tissues, with maximal uptake in kidney followed by liver, spleen, vertebral body, tumour, spinal cord, lung, and muscle at baseline.
  • In a pt with mesothelioma who also had a second [<sup>11</sup>C]LY2181308-PET scan during LY2181308 treatment infusion, there was about 2-fold increase in [<sup>11</sup>C]LY2181308 tumour uptake, in contrast to markedly reduced uptake in kidneys, liver, and spleen and similar aortic (circulatory) [<sup>11</sup>C]LY2181308 levels.
  • In this patient, tumour [<sup>18</sup>F]FDG- PET uptake at 28 days was reduced by up to 40% after treatment, suggesting drug activity.
  • CONCLUSIONS: [<sup>11</sup>C]LY2181308 pharmacokinetics suggest biologically active human tumour drug concentrations can be attained.
  • LY2181308 therapy saturated normal tissue kinetics and increased tumour uptake of [<sup>11</sup>C]LY2181308.
  • Data uniquely obtained from fully regulated microdosing studies may rationalise and hasten drug development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961712.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Graefe T, Lubbing C, Bolling C, Muller-Hagen S, Leisner B, Fleet J, Ludtke FE, Blatter J, Suri A, Hanauske AR: Phase I study of pemetrexed plus paclitaxel in patients with solid tumor. J Clin Oncol; 2004 Jul 15;22(14_suppl):2103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 45 pts [31 M, 14 F; median age 59 (range 31-77); WHO performance status 0-1 (86.7%); prior chemotherapy (53.3%)] were enrolled.
  • Three drug-related discontinuations were anorexia, thrombocytopenia, and pancytopenia.
  • Stable disease occurred in pts with mesothelioma (3) and esophagus (2) cancers, and 1 pt each with thyroid, head and neck, lung, liver, pancreas, prostate, renal, and stomach cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28017047.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Buchholz BM, Gütgemann I, Fischer HP, Gorschlüter M, Türler A, Kalff JC, Hirner A, Standop J: Lymph node dissection in primary intrahepatic malignant mesothelioma: case report and implications for diagnosis and therapy. Langenbecks Arch Surg; 2009 Nov;394(6):1123-30
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node dissection in primary intrahepatic malignant mesothelioma: case report and implications for diagnosis and therapy.
  • INTRODUCTION: In this rare case of intrahepatic malignant mesothelioma with subsequent lymph node metastases, hepatic segmentectomy in combination with repeated lymphadenectomy resulted in prolonged survival, currently 37 months after initial diagnosis.
  • DISCUSSION: Immunohistochemically, vascular endothelial growth factor receptor-1 expressing tumor cells were surrounded by a dense D 2-40-positive lymphangiovascular network, suggesting tumor induced lymphangiogenesis correlating to 2-deoxy-2[(18)F]fluoro-d-glucose-positron emission tomography/computed tomography-positive recurrent intraabdominal and intrathoracic lymphatic tumor spread.
  • Therefore, extended lymphadenectomy during primary tumor resection and combined adjuvant chemotherapy with promising anticancer agents possessing antilymphangiogenic and antimetabolite properties should be considered to prolong survival in cases of extrathoracic malignant mesothelioma.
  • [MeSH-major] Hepatectomy. Liver Neoplasms / pathology. Liver Neoplasms / surgery. Lymph Node Excision. Mesothelioma / secondary. Mesothelioma / surgery

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Chem. 1992 Nov 13;35(23):4450-4 [1447744.001]
  • [Cites] Semin Oncol. 2005 Jun;32(3):336-50 [15988688.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] Chir Ital. 2002 Nov-Dec;54(6):897-902 [12613343.001]
  • [Cites] Leukemia. 2004 Jun;18(6):1054-8 [15057248.001]
  • [Cites] J Thorac Oncol. 2006 Feb;1(2):169-71 [17409848.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2431-9 [10873096.001]
  • [Cites] Eur J Radiol. 2007 Dec;64(3):356-66 [17954021.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4587-93 [17008700.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):893-903 [11549582.001]
  • [Cites] J Investig Dermatol Symp Proc. 2000 Dec;5(1):14-9 [11147669.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):658-64 [18174461.001]
  • [Cites] Magn Reson Imaging. 2003 Nov;21(9):1091-3 [14684216.001]
  • [Cites] Virchows Arch. 2006 May;448(5):655-8 [16541281.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1010-7 [17032920.001]
  • [Cites] Urology. 1982 Sep;20(3):316-9 [7123728.001]
  • [Cites] Pathol Int. 1996 May;46(5):389-91 [8809888.001]
  • [Cites] Gastrointest Radiol. 1992 Spring;17 (2):129-31 [1551507.001]
  • [Cites] Zentralbl Chir. 1996;121(7):587-90 [8967200.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1183-200 [10976692.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Jun;4(6):344-52 [17534390.001]
  • [Cites] APMIS. 2002 Nov;110(11):789-94 [12588419.001]
  • [Cites] Cancer Cell. 2005 Feb;7(2):121-7 [15710325.001]
  • [Cites] J Thorac Imaging. 2006 May;21(2):146-53 [16770231.001]
  • [Cites] Nat Med. 2001 Feb;7(2):186-91 [11175849.001]
  • [Cites] J Clin Invest. 2004 Apr;113(7):1040-50 [15057311.001]
  • [Cites] Cancer Res. 1970 May;30(5):1287-308 [4316726.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):54-61 [10487612.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5918-25 [17908988.001]
  • [Cites] Nat Med. 2001 Feb;7(2):151-2 [11175837.001]
  • [Cites] Mod Pathol. 2008 Mar;21(3):256-64 [18192971.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1116-23 [9067281.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):645-6 [11792939.001]
  • [Cites] Int J Surg Pathol. 2004 Jan;12(1):87-91 [14765281.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • (PMID = 19280219.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Krastev Z, Koltchakov V, Tomov B, Koten JW: Non-melanoma and non-renal cell carcinoma malignancies treated with interleukin-2. Hepatogastroenterology; 2003 Jul-Aug;50(52):1006-16
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some positive results have been observed after interleukin-2 treatment, especially in melanoma, and pulmonary metastasis of renal carcinoma.
  • The response was studied with reference to the interleukin-2 dose, the way of application, the kind of tumor and the other treatments.
  • A database search was performed to trace studies describing interleukin-2 tumor treatment in non-melanoma and non-renal cells malignancies, published between 1.1.1999 and 30.01.2001.
  • In malignant mesothelioma--stable disease was achieved in 56% with potential advantages of local application.
  • In hematological malignancies interleukin-2 treatment was followed by remission or increase in immune defense depending on the histological type.
  • The maintenance treatment with low doses of interleukin-2 in responders to previous chemotherapy is promising.
  • Better results are observed with lower dose, cyclic application and combining chemotherapy.
  • Cycles with longer duration (4-6 months) have a better effect also for patients with response to former treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Interleukin-2 / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Breast Neoplasms / drug therapy. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Hematologic Neoplasms / drug therapy. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Mesothelioma / drug therapy. Pancreatic Neoplasms / drug therapy. Pleural Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12845968.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2
  • [Number-of-references] 42
  •  go-up   go-down


17. Fisher KD, Green NK, Hale A, Subr V, Ulbrich K, Seymour LW: Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. J Drug Target; 2007 Aug-Sep;15(7-8):546-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy.
  • Here we show that polymer-coating adenovirus (pc-virus) abrogates its normal infectivity in vitro and also in liver following intravenous injection.
  • The coated virus accumulates within solid subcutaneous AB22 mesothelioma tumours 40-times more than unmodified virus, and mediates higher levels of transgene expression within tumours.
  • This is the first demonstration of passive tumour targeting of polymer-coated adenoviruses administered by intravenous injection, and also the first time pc-virus has been shown to be infectious following passive targeting to tumours in vivo.
  • This technology provides an interesting option for delivery of therapeutic viruses to disseminated tumour masses by intravenous injection.
  • [MeSH-major] Adenoviridae. Gene Targeting / methods. Genetic Therapy / methods. Mesothelioma / therapy. Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671901.001).
  • [ISSN] 1061-186X
  • [Journal-full-title] Journal of drug targeting
  • [ISO-abbreviation] J Drug Target
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Polymers
  •  go-up   go-down


18. Verschraegen CF, Kumagai S, Davidson R, Feig B, Mansfield P, Lee SJ, Maclean DS, Hu W, Khokhar AR, Siddik ZH: Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol; 2003 Oct;129(10):549-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.
  • METHODS: Eligible patients had normal renal, hematologic, and liver functions.
  • Laparoscopy was performed on the first two courses for evaluation, adhesiolysis, and chemotherapy administration.
  • Afterwards, chemotherapy was administered through a peritoneal catheter.
  • Diagnoses were: malignant mesothelioma (six patients), signet ring cell (three), colon adenocarcinoma, pseudomyxoma peritonei, gastrointestinal stromal tumor (two each), and ovarian carcinoma (one).
  • Pharmacokinetics studies indicated a rapid but low absorption of drug into the systemic circulation, with a prolonged retention of platinum in the plasma compartment.
  • Peritoneal L-NDDP exposure was 17 to 49-times greater than in the plasma compartment.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adult. Aged. Area Under Curve. Ascites / metabolism. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / metabolism. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / metabolism. Endometrial Stromal Tumors / drug therapy. Endometrial Stromal Tumors / metabolism. Female. Humans. Injections, Intraperitoneal. Liposomes. Male. Mesothelioma / drug therapy. Mesothelioma / metabolism. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism. Peritoneum / diagnostic imaging. Peritoneum / metabolism. Radionuclide Imaging. Technetium. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1988 Aug 15;48(16):4509-12 [3396003.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;28(4):315-7 [1879050.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):884-91 [9041149.001]
  • [Cites] Semin Oncol. 1994 Apr;21(2 Suppl 2):17-9; quiz 20, 58 [8202717.001]
  • [Cites] Cancer Chemother Pharmacol. 1988;21(1):57-60 [3277734.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Jun;49(6):499-503 [12107555.001]
  • [Cites] Surg Oncol Clin N Am. 2001 Oct;10(4):915-33, xi [11641098.001]
  • [Cites] N Engl J Med. 1996 Dec 26;335(26):1950-5 [8960474.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1776-82 [11813623.001]
  • [Cites] J Med Chem. 1991 Jan;34(1):325-9 [1992134.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1237-41 [11948138.001]
  • [Cites] Surg Clin North Am. 1978 Feb;58(1):131-42 [417410.001]
  • [Cites] Anal Biochem. 1987 May 15;163(1):21-6 [3039867.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2961-7 [8523061.001]
  • [Cites] Clin Cancer Res. 1997 Mar;3(3):373-9 [9815694.001]
  • [Cites] Surgery. 1993 Jun;113(6):631-6 [8506520.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(1):1-8 [2720887.001]
  • [Cites] Semin Oncol. 1985 Sep;12(3 Suppl 4):23-8 [4048973.001]
  • [Cites] Dis Colon Rectum. 1993 Apr;36(4):323-9 [8458256.001]
  • [Cites] Cancer Res. 1990 Jul 15;50(14):4254-9 [2364384.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3944-6 [12351590.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2622-9 [8640714.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2048-52 [8156509.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):232-7 [3121165.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1001-7 [11181662.001]
  • [Cites] J Microencapsul. 1994 Jan-Feb;11(1):41-54 [8138874.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):65-71 [2104572.001]
  • (PMID = 14513369.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 0 / Organoplatinum Compounds; 113427-19-3 / bis-neodecanoato-1,2-diaminocyclohexaneplatinum(II); 7440-26-8 / Technetium
  •  go-up   go-down


19. Medved M, Karczmar G, Yang C, Dignam J, Gajewski TF, Kindler H, Vokes E, MacEneany P, Mitchell MT, Stadler WM: Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging; 2004 Jul;20(1):122-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time.
  • PURPOSE: To evaluate variability of a simplified method for measuring semiquantitative DCE-MRI parameters in patients with cancer and to explore effects of treatment with a putative anti-angiogenic compound.
  • MATERIALS AND METHODS: A total of 19 patients enrolled on treatment trials with the putative anti-angiogenic agent SU5416 underwent contrast enhanced examinations, and 11 had a second examination eight weeks post therapy.
  • Contrast media concentration as a function of time was calculated using changes in signal and literature baseline T(1) values in normal muscle or liver reference tissue.
  • Semiquantitative DCE-MRI parameters, including the area under the contrast concentration vs. time curve (AUC), were calculated for regions-of-interest in normal liver and muscle, and in tumors.
  • RESULTS: The coefficients of variation for pretherapy parameters in normal tissue were 11% to 37%.
  • No significant changes were detected in normal liver over two months of therapy.
  • CONCLUSION: Variability of semiquantitative DCE-MRI parameters utilizing a method based on known T(1) values in a reference tissue is low enough to detect changes in tumors during therapy.
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Colonic Neoplasms / diagnosis. Colonic Neoplasms / drug therapy. Gadolinium DTPA. Humans. Indoles / therapeutic use. Liver / anatomy & histology. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Melanoma / diagnosis. Melanoma / drug therapy. Melanoma / secondary. Mesothelioma / diagnosis. Mesothelioma / drug therapy. Muscle, Skeletal / anatomy & histology. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrroles / therapeutic use

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15221817.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 P30 CA14599-29; United States / NCI NIH HHS / CM / N01 CM17102-02; United States / NCI NIH HHS / CA / P30 CA14599
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Contrast Media; 0 / Indoles; 0 / Pyrroles; 71IA9S35AJ / Semaxinib; 84F6U3J2R6 / gadodiamide; EC 2.7.10.1 / Protein-Tyrosine Kinases; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


20. Culy CR, Clemett D, Wiseman LR: Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs; 2000 Oct;60(4):895-924
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
  • The highest response rates were achieved when oxaliplatin was used in combination with fluorouracil/folinic acid (leucovorin; calcium folinate), typically > or = 50% in the first-line setting and 13 to 45% as a second-line therapy.
  • First-line triple therapy with oxaliplatin and fuorouracil/folinic acid achieved significantly higher response rates and longer median progression-free survival than fluorouracil/folinic acid therapy alone.
  • This may be a consequence of the subsequent use of oxaliplatin and/or surgery after disease progression in patients who relapsed after fluorouracil/folinic acid therapy alone.
  • Neoadjuvant therapy with oxaliplatin/fluorouracil/folinic acid has proven beneficial in enabling surgical removal of previously unresectable liver metastases.
  • In 2 studies, surgery with curative intent was performed in 16 and 51% of patients with initially unresectable liver metastases following oxaliplatin/fluorouracil/folinic acid therapy; the 5-year survival rates were 40 and 50%, respectively.
  • In patients with advanced ovarian cancer, first-line therapy with oxaliplatin/cyclophosphamide achieved an objective response rate which did not differ significantly from that of cisplatin/cyclophosphamide (33 vs 42%).
  • Promising results have also been found with oxaliplatin in patients with non-Hodgkin's lymphoma, breast cancer, mesothelioma and non-small cell lung cancer.
  • Reversible, cumulative, peripheral sensory neuropathy is the principle dose-limiting factor of oxaliplatin therapy.
  • CONCLUSION: Oxaliplatin in combination with fluorouracil/folinic acid is an effective treatment option for patients with metastatic colorectal cancer, both as a first-line therapy and in patients refractory to previous chemotherapy.
  • [MeSH-major] Antineoplastic Agents. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Organoplatinum Compounds. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Animals. Biotransformation. Clinical Trials as Topic. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Metabolic Clearance Rate. Tumor Cells, Cultured / drug effects

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1995 Mar-Apr;15(2):393-8 [7763011.001]
  • [Cites] Drug Saf. 1995 Oct;13(4):228-44 [8573296.001]
  • [Cites] Ann Oncol. 1996 Dec;7(10):1065-70 [9037366.001]
  • [Cites] J Clin Oncol. 1999 Jun;17 (6):1751-9 [10561212.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):1124-7 [9849465.001]
  • [Cites] Ann Oncol. 1999 Nov;10(11):1311-6 [10631458.001]
  • [Cites] Lancet. 1994 Jun 4;343(8910):1405-10 [7515134.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2529-35 [9796987.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 6;91(1):91-2 [9890180.001]
  • [Cites] Br J Cancer. 1989 Apr;59(4):527-34 [2653399.001]
  • [Cites] Eur J Cancer. 1998 Sep;34(10):1522-34 [9893623.001]
  • [Cites] J Inorg Biochem. 1999 Oct;77(1-2):71-81 [10626357.001]
  • [Cites] Br J Cancer. 1989 Nov;60(5):767-9 [2803953.001]
  • [Cites] Ann Oncol. 1998 Oct;9(10):1053-71 [9834817.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3968-71 [10463593.001]
  • [Cites] Biomed Pharmacother. 1989;43(4):237-50 [2675999.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5970-6 [8261411.001]
  • [Cites] Eur J Cancer. 1999 Sep;35(9):1338-42 [10658524.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(2):157-64 [10663631.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):136-47 [10623704.001]
  • [Cites] Drugs Aging. 1999 Jun;14(6):459-75 [10408744.001]
  • [Cites] Ann Oncol. 2000 Feb;11(2):163-7 [10761750.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):513-4 [1548513.001]
  • [Cites] Ann Oncol. 1999 Mar;10(3):351-4 [10355582.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;36(4):271-8 [7628045.001]
  • [Cites] Lancet. 1997 Sep 6;350(9079):681-6 [9291901.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):160 [9450578.001]
  • [Cites] J Clin Oncol. 1999 Mar;17 (3):902-6 [10071282.001]
  • [Cites] Cancer Res. 1997 May 15;57(10):1841-5 [9157971.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):1021-9 [9563898.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1205-18 [10778943.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2293-300 [10829050.001]
  • [Cites] Mol Pharmacol. 1998 Nov;54(5):770-7 [9804612.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1193-202 [10715288.001]
  • [Cites] Eur J Cancer. 1991;27(2):135-8 [1827275.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2950-8 [8918492.001]
  • [Cites] Eur J Cancer. 1993;29A(3):359-62 [8398335.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):105-8 [9541691.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1407-12 [9807986.001]
  • [Cites] Cancer Lett. 1985 Jun;27(2):135-43 [4039973.001]
  • [Cites] Eur J Cancer. 1993;29A(9):1280-4 [8343268.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Jul;32B(4):278-9 [8776427.001]
  • [Cites] Rev Med Interne. 1997;18(10):769-75 [9500010.001]
  • [Cites] Eur J Cancer. 1999 Mar;35 Suppl 1:S9-13 [10645208.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2532-40 [10375099.001]
  • [Cites] Eur J Cancer. 1997 Aug;33(9):1400-6 [9337681.001]
  • [Cites] Semin Oncol. 1999 Dec;26(6):589-605 [10606252.001]
  • [Cites] Ann Oncol. 1996 Nov;7(9):961-5 [9006748.001]
  • [Cites] Cancer Lett. 1996 Jul 19;105(1):5-14 [8689632.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):893-900 [1735081.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3500-5 [8012973.001]
  • [Cites] Gynecol Oncol. 1995 Jul;58(1):106-9 [7789874.001]
  • [Cites] Cancer Res. 1988 Jan 1;48(1):9-13 [3335002.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(2):117-23 [10412945.001]
  • [Cites] Eur J Cancer. 1998 Apr;34(5):619-26 [9713264.001]
  • [Cites] Oncol Res. 1996;8(10-11):415-23 [9114434.001]
  • [Cites] Clin Pharmacokinet. 2000 Jan;38(1):1-21 [10668856.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):340-8 [9633846.001]
  • [Cites] Ann Oncol. 1999 Sep;10(9):1125-8 [10572615.001]
  • [Cites] Ann Oncol. 1996 Jan;7(1):95-8 [9081400.001]
  • [Cites] Drugs. 1998 Mar;55(3):423-35 [9530547.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3560-8 [10550155.001]
  • [Cites] Biochem Pharmacol. 1996 Dec 24;52(12):1855-65 [8951344.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;25(4):299-303 [2295116.001]
  • [Cites] Clin Cancer Res. 1997 Jun;3(6):891-9 [9815764.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] Ann Oncol. 1999 May;10(5):610 [10416017.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1189-96 [10353756.001]
  • [Cites] Br J Cancer. 1995 Jun;71(6):1302-7 [7779728.001]
  • [Cites] Drugs. 1996 Oct;52(4):606-23 [8891470.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2 Suppl 5):4-12 [9609103.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1297-8 [9849497.001]
  • [Cites] Semin Oncol. 1999 Feb;26(1 Suppl 5):1-5 [10213008.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1608-17 [7932825.001]
  • [Cites] Ann Oncol. 1998 Nov;9(11):1251-3 [9862058.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):663-9 [10442188.001]
  • [Cites] Invest New Drugs. 1997;15(2):109-14 [9220289.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] Br J Cancer. 1998 Jun;77 Suppl 4:4-7 [9647612.001]
  • [Cites] Eur J Cancer. 1997 Feb;33(2):214-9 [9135491.001]
  • [Cites] Ann Surg. 1996 Oct;224(4):509-20; discussion 520-2 [8857855.001]
  • [Cites] Anticancer Drugs. 1997 Oct;8(9):876-85 [9402315.001]
  • [Cites] Ann Oncol. 2000 Apr;11(4):461-8 [10847467.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3579-85 [9721864.001]
  • [Cites] Semin Oncol. 1999 Feb;26(1 Suppl 1):8-14 [10071969.001]
  • [Cites] Biomed Pharmacother. 1989;43(4):251-60 [2790145.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):4881-6 [8895738.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2739-44 [9704726.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):896-903 [1534121.001]
  • [Cites] Anticancer Drugs. 1998 Apr;9(4):301-5 [9635919.001]
  • [Cites] Eur J Cancer. 1999 Jan;35(1):86-90 [10211093.001]
  • (PMID = 11085200.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Number-of-references] 143
  •  go-up   go-down


21. Schmid KE, Kornek GV, Schüll B, Raderer M, Lenauer A, Depisch D, Lang F, Scheithauer W: Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed. Onkologie; 2003 Jun;26(3):255-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed.
  • BACKGROUND: Treatment with oxaliplatin plus raltitrexed has demonstrated an encouraging therapeutic index in patients with advanced colorectal cancer and malignant pleural mesothelioma.
  • The aim of this multi-institutional study was to determine the antitumor potential of this combination in patients with metastatic gastric cancer failing prior palliative first-line chemotherapy, and to reconfirm its favorable toxicity profile.
  • PATIENTS AND METHODS: 21 patients with metastatic gastric cancer, who progressed while on or within 6 months after discontinuing palliative first-line chemotherapy, participated in this study.
  • Median progression-free and overall survival from the onset of salvage chemotherapy was 2.0 and 4.5 months, respectively.
  • The most frequent non-hematologic adverse events included nausea/emesis, asthenia, and transient elevation of liver functional parameters, again with grade 3 symptoms occurring only in a minority of patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Palliative Care. Salvage Therapy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger GmbH, Freiburg
  • [CommentIn] Onkologie. 2003 Jun;26(3):214-5 [12845204.001]
  • (PMID = 12845210.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Quinazolines; 0 / Thiophenes; 04ZR38536J / oxaliplatin; FCB9EGG971 / raltitrexed
  •  go-up   go-down


22. Ceelen WP, Peeters M, Houtmeyers P, Breusegem C, De Somer F, Pattyn P: Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis. Ann Surg Oncol; 2008 Feb;15(2):535-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed the safety and efficacy of HIPEC using high-dose oxaliplatin, a cytotoxic agent commonly used in metastatic colorectal cancer and showing promising activity in ovarian cancer and mesothelioma.
  • Major morbidity developed in 24% of patients, while 30-day mortality did not occur.
  • One patient developed unexplained repeated episodes of hemoperitoneum.
  • After a mean follow-up time of 14.5 months, nine patients died from disease progression.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Organoplatinum Compounds / administration & dosage. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Gastrointestinal Neoplasms / pathology. Humans. Hyperthermia, Induced. Injections, Intraperitoneal. Length of Stay. Liver / drug effects. Male. Middle Aged. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17960463.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  •  go-up   go-down


23. Mercadante S, Casuccio A, Pumo S, Fulfaro F: Opioid responsiveness-primary diagnosis relationship in advanced cancer patients followed at home. J Pain Symptom Manage; 2000 Jul;20(1):27-34
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the group of 181 patients, somatic pain was associated with lung, head and neck, breast, and prostate cancer (p < 0.0005), while visceral pain was associated with colorectal, gastric, liver, pancreatic, and uterine cancer (p < 0.0005).
  • A significant dose increase was observed only for mesothelioma (p = 0.
  • 027) when compared with other types of cancer.
  • [MeSH-major] Analgesics, Opioid / therapeutic use. Neoplasms / complications. Pain / drug therapy. Pain / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10946166.001).
  • [ISSN] 0885-3924
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Analgesics, Opioid
  •  go-up   go-down






Advertisement